Lingxiang Yu
No. 28 Fuxing Road
Beijing, 100853, China
Beijing, 100853, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications
Skin commensal Cutibacterium acnes alleviates UVB-induced solar dermatitis via ceramide-mediated TLR4-MyD88-NF-κB.
Journal: Free radical biology & medicine
Published: October 18, 2025
Risk of hepatocellular carcinoma occurrence after antiviral therapy for patients with chronic hepatitis C Infection: a systematic review and meta-analysis.
Journal: Hepatology international
Published: January 23, 2024
Efficacy and safety of robotic versus laparoscopic liver resection for hepatocellular carcinoma: a propensity score-matched retrospective cohort study.
Journal: Hepatology international
Published: December 08, 2023
Construction and Validation of a Novel Nomogram Predicting Recurrence in Alpha-Fetoprotein-Negative Hepatocellular Carcinoma Post-Surgery Using an Innovative Liver Function-Nutrition-Inflammation-Immune (LFNII) Score: A Bicentric Investigation.
Journal: Journal of hepatocellular carcinoma
Published: November 29, 2023
Artesunate Sensitizes human hepatocellular carcinoma to sorafenib via exacerbating AFAP1L2-SRC-FUNDC1 axis-dependent mitophagy.
Journal: Autophagy
Published: September 21, 2023
DEB-TACE with irinotecan versus C-TACE for unresectable intrahepatic cholangiocarcinoma: a prospective clinical study.
Journal: Frontiers in bioengineering and biotechnology
Published: November 30, 2022
A multi-center retrospective study on the efficacy and safety of regorafenib vs. regorafenib combined with PD-1 inhibitors as a second-line therapy in patients with advanced hepatocellular carcinoma.
Journal: Annals of translational medicine
Published: October 31, 2022
Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients.
Journal: Hepatology international
Published: October 11, 2022
Efficacy and Safety of TKI Plus PD-1 Inhibitors in Elderly uHCC Patients: A Retrospective Study.
Journal: Journal of hepatocellular carcinoma
Published: August 31, 2022
The advanced development of molecular targeted therapy for hepatocellular carcinoma.
Journal: Cancer biology & medicine
Published: June 14, 2022
Preclinical investigation of artesunate as a therapeutic agent for hepatocellular carcinoma via impairment of glucosylceramidase-mediated autophagic degradation.
Journal: Experimental & molecular medicine
Published: December 22, 2021
Last Updated: 09/26/2026